BOONVILLE, NY – VestraCare, an operator of high-quality nursing and rehabilitation facilities, is pleased to announce that its Sunset Nursing and Rehabilitation Center is now offering monoclonal antibody infusions for the treatment of high-risk Covid-19 patients.
In November 2020, the FDA (Food and Drug Administration) issued EUA (emergency use authorization) for the use of monoclonal antibodies for the treatment of high-risk patients with mild to moderate Covid-19 symptoms at risk for progression to severe illness and hospitalization.
Sunset has the advanced clinical setting necessary to administer the infusions, as well as a highly skilled nursing staff and on-site medical providers. “We’re happy to be able to offer this progressive form of treatment to our residents,” stated Administrator Robert Baranello.
The clinical team at Sunset has been working closely with its Medical Director, Todd Podkowka, D.O., to implement protocols for administration and aftercare in concert with those specified in the EUA.
The antibodies are made with proteins created in a laboratory and are designed to mimic the antibodies created in the body’s immune system to ward off the virus and fight infection. Sunset will receive the compounded medication from LIScripts on a per-patient basis.
Residents will receive the treatment in-house in the comfort of a familiar environment. The team at Sunset provides continuous monitoring in a designated area prior, during and post-infusion.
Sunset Nursing and Rehabilitation Center provides 24-hour skilled nursing care, subacute rehabilitation and short-term respite care. For more information, visit http://www.sunsetnrc.com.